|
1
|
Hann CL and Rudin CM: Management of
small-cell lung cancer: Incremental changes but hope for the
future. Oncology (Williston Park). 22:1486–1492. 2008.PubMed/NCBI
|
|
2
|
Pujol JL, Daurès JP, Rivière A, et al:
Etoposide plus cisplatin with or without the combination of
4′-epidoxorubicin plus cyclophosphamide in treatment of extensive
small-cell lung cancer: A French Federation of Cancer Institutes
multicenter phase III randomized study. J Natl Cancer Inst.
93:300–308. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Niell HB, Herndon JE II, Miller AA, et al:
Cancer and Leukemia Group: Randomized phase III intergroup trial of
etoposide and cisplatin with or without paclitaxel and granulocyte
colony-stimulating factor in patients with extensive-stage
small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J
Clin Oncol. 23:3752–3759. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schiller JH, Adak S, Cella D, DeVore RF
III and Johnson DH: Topotecan versus observation after cisplatin
plus etoposide in extensive-stage small-cell lung cancer: E7593 - a
phase III trial of the Eastern Cooperative Oncology Group. J Clin
Oncol. 19:2114–2122. 2001.PubMed/NCBI
|
|
5
|
Fukuoka M, Furuse K, Saijo N, Nishiwaki Y,
Ikegami H, Tamura T, Shimoyama M and Suemasu K: Randomized trial of
cyclophosphamide, doxorubicin and vincristine versus cisplatin and
etoposide versus alternation of these regimens in small-cell lung
cancer. J Natl Cancer Inst. 83:855–861. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Roth BJ, Johnson DH, Einhorn LH, et al:
Randomized study of cyclophosphamide, doxorubicin and vincristine
versus etoposide and cisplatin versus alternation of these two
regimens in extensive small-cell lung cancer: A phase III trial of
the Southeastern Cancer Study Group. J Clin Oncol. 10:282–291.
1992.PubMed/NCBI
|
|
7
|
Ihde DC, Mulshine JL, Kramer BS, et al:
Prospective randomized comparison of high-dose and standard-dose
etoposide and cisplatin chemotherapy in patients with
extensive-stage small-cell lung cancer. J Clin Oncol. 12:2022–2034.
1994.PubMed/NCBI
|
|
8
|
Thatcher N, Girling DJ, Hopwood P,
Sambrook RJ, Qian W and Stephens RJ: Improving survival without
reducing quality of life in small-cell lung cancer patients by
increasing the dose-intensity of chemotherapy with granulocyte
colony-stimulating factor support: Results of a British Medical
Research Council Multicenter Randomized Trial. Medical Research
Council Lung Cancer Working Party. J Clin Oncol. 18:395–404.
2000.PubMed/NCBI
|
|
9
|
Noda K, Nishiwaki Y, Kawahara M, et al:
Japan Clinical Oncology Group: Irinotecan plus cisplatin compared
with etoposide plus cisplatin for extensive small-cell lung cancer.
N Engl J Med. 346:85–91. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hanna N, Bunn PA Jr, Langer C, et al:
Randomized phase III trial comparing irinotecan/cisplatin with
etoposide/cisplatin in patients with previously untreated
extensive-stage disease small-cell lung cancer. J Clin Oncol.
24:2038–2043. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lara PN Jr, Natale R, Crowley J, et al:
Phase III trial of irinotecan/cisplatin compared with
etoposide/cisplatin in extensive-stage small-cell lung cancer:
Clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol.
27:2530–2535. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Foster NR, Qi Y, Shi Q, Krook JE, Kugler
JW, Jett JR, Molina JR, Schild SE, Adjei AA and Mandrekar SJ: Tumor
response and progression-free survival as potential surrogate
endpoints for overall survival in extensive stage small-cell lung
cancer: Findings on the basis of North Central Cancer Treatment
Group trials. Cancer. 117:1262–1271. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hande KR: Etoposide: Four decades of
development of a topoisomerase II inhibitor. Eur J Cancer.
34:1514–1521. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Slevin ML, Clark PI, Joel SP, Malik S,
Osborne RJ, Gregory WM, Lowe DG, Reznek RH and Wrigley PF: A
randomized trial to evaluate the effect of schedule on the activity
of etoposide in small-cell lung cancer. J Clin Oncol. 7:1333–1340.
1989.PubMed/NCBI
|
|
15
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: Revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
National Cancer Institute: Common
Terminology Criteria for Adverse Events (CTCAE) v4.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htmAccessed.
May 28–2009
|
|
17
|
Oze I, Hotta K, Kiura K, Ochi N, Takigawa
N, Fujiwara Y, Tabata M and Tanimoto M: Twenty-seven years of phase
III trials for patients with extensive disease small-cell lung
cancer: Disappointing results. PLoS One. 4:e78352009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fink TH, Huber RM, Heigener DF, et al:
‘Aktion Bronchialkarzinom’ (ABC Study Group): Topotecan/cisplatin
compared with cisplatin/etoposide as first-line treatment for
patients with extensive disease small-cell lung cancer: Final
results of a randomized phase III trial. J Thorac Oncol.
7:1432–1439. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schmittel A, Sebastian M, Fischer von
Weikersthal L, et al: Arbeitsgemeinschaft Internistische Onkologie
Thoracic Oncology Study Group: A German multicenter, randomized
phase III trial comparing irinotecan-carboplatin with
etoposide-carboplatin as first-line therapy for extensive-disease
small-cell lung cancer. Ann Oncol. 22:1798–1804. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
de Jong WK, Groen HJM, Koolen MGJ, Biesma
B, Willems LN, Kwa HB, van Bochove A, van Tinteren H and Smit EF:
Phase III study of cyclophosphamide, doxorubicin, and etoposide
compared with carboplatin and paclitaxel in patients with extensive
disease small-cell lung cancer. Eur J Cancer. 43:2345–2350. 2007.
View Article : Google Scholar : PubMed/NCBI
|
